Novel pan-cancer T cell exhaustion signature forecasts immunotherapy response and unveils BCAP31 in macrophages as a therapeutic target in neuroblastoma

新型泛癌T细胞耗竭特征预测免疫疗法反应,并揭示巨噬细胞中的BCAP31是神经母细胞瘤的治疗靶点

阅读:1

Abstract

INTRODUCTION: Gaining insights into the molecular features associated with T cell exhaustion (TEX) can offer fresh perspectives on predicting treatment responses, and we aim to investigate TEX-related tumor associated macrophages (TAM) subset to deeply understand underlying mechanisms of immune exhaustion. METHODS: We performed pan-cancer single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics RNA sequencing (stRNA-seq) analyses to investigate the subtype of TEX-associated TAMs, exploring its spatial distribution characteristics in context of immunotherapy. The pan-cancer scRNA-seq and RNA-seq datasets were incorporated to develop the STMN2+ Macrophage Signature (STMN2.SIG), which predicts immunotherapy response based on integrative machine learning techniques. Comprehensive scRNA-seq analysis, with in vitro experiments, investigated the mechanisms by which STMN2+ TAMs influence tumor progression and immune exhaustion. RESULTS: A macrophage subset, STMN2+ TAMs, and an epithelial subtype, S phase Sympathoblasts were identified as TEX-related cellular subpopulations. A higher proportion of STMN2+ TAMs was observed in non-responders compared to responders in pan-cancer immunotherapy landscape. Pan-cancer STMN2.SIG performed well in predicting immunotherapy response in pan-cancer cohorts, potentially linked to intercellular interactions between STMN2+ TAMs and CD8+ Tex cells. stRNA-seq analysis confirmed that interactions and cellular distances between STMN2+ TAMs and CD8+ Tex cells impact therapy efficacy. In a co-culture system, silencing BCAP31 on TAMs drives CD8+ T cells toward an effector state in NB. And BCAP31 on TAMs is associated with modulation of JAK2-STAT3 pathway in tumor cells. CONCLUSION: Our study provides pan-cancer STMN2.SIG as an outperforming approach for patient selection of immunotherapy, and advances our understanding of TAM biology and suggests potential therapeutic strategies for downregulation of BCAP31 in TAMs.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。